Psilocybin, Brain Health and Longevity

In the second wave of psychedelic research, there are multiple trials taking place across the world.

This includes looking into their potential use to treat end-of-life anxiety and depression in the terminally ill (at the US’s John Hopkins University and NYU), for smoking cessation, alcoholism, anorexia, OCD, asthma, longevity and pain syndromes, as well as seven separate trials worldwide into the use of psilocybin to treat depression.

Read more

Psychedelics or SSRI's?

This new research looks at the effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder.

The study found that six-week intensive treatments with either psilocybin or escitalopram (with psychological support) for MDD were associated with long-term improvements in depressive symptom severity. The greater degree of improvement in the PT arm at follow-up on psychosocial functioning, meaning in life, and psychological connectedness suggests warrant future research.

Read more